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Synthesis and evaluation of chromone-2-carboxamide derivatives as
cytotoxic agents and 5-lipoxygenase inhibitors
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Abstract In the present study, we prepared a series of 21
chromone carboxamide derivatives bearing diverse amide
side chains. Their potency to inhibit the proliferation of
breast (MCF-7), ovarian (OVCAR and IGROV), and colon
(HCT-116) cancer cell lines, was evaluated in vitro using
the MTT assay. Among these compounds, 13 showed
promising cytotoxic activity against at least one cancer cell
line with IC50 in the range 0.9–10 μM. Our compounds
were also screened for their anti-inﬂammatory activity as
putative inhibitors of 5-lipoxygenase.
Structure-activity relationships studies on our chromone
carboxamide derivatives revealed that the presence of a 6-
ﬂuoro substituent on the chromone nucleus (R1) or propyl
and 3-ethylphenyl groups on the amide side chain (R2) has
a positive impact on the cytotoxic activity. In terms
of the anti-inﬂammatory activity, hydrophilic chromone
carboxamide derivatives showed greater 5-lipoxygenase
inhibition.
The physico-chemical properties of chromone carbox-
amides are in accordance with the general requirements of
drug development process and ligand efﬁciency values
allow further structure optimization, with compound 4b as
a lead.
Keywords Chromone carboxamides ● Cytotoxic activity ●
Anti-inﬂammatory effect ● Lipophilicity ● SAR
Introduction
The chromone scaffold [(4H)-1-benzopyran-4-one] is well
known as a pharmacophore of a large number of natural and
synthetic bioactive molecules. This heterocycle constitutes
the basic nucleus of ﬂavones, an important and widespread
class of compounds from plants with a large number of
biological activities (Gaspar et al., 2014, Keri et al., 2014).
Natural and synthetic chromones have shown a large
spectrum of biological activities such as anti-inﬂammatory
(Khan et al., 2010, Thanigaimalai et al., 2010), antimalarial
(Auffret et al., 2007), and anticancer activity (Budzisz et al.,
2002, Barve et al., 2006), associated with low toxicity (do
Rocio Andrade Pires et al., 2016)
With 8.2 million deaths and 14.1 million new cases in
2012 (WHO, 2013), and given the fact that this number will
reach 22.2 million by 2030, cancer has become one of the
major health problems worldwide (Bray et al., 2012). The
situation is expected to worsen because of the increase of
multidrug resistances in various types of cancer (e.g., breast,
ovarian, gastrointestinal, lung cancers) making the devel-
opment of new active compounds a real challenge for the
coming years (Pan et al., 2016).
In the search for new efﬁcient anticancer drugs, chro-
mones in particular carboxamides, can play an important
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role as demonstrated by the growing interest toward this
class of compounds. Indeed, several chromone carbox-
amides have been reported as potent and selective cytotoxic
agents (Bhatnagar et al., 2010, Nam et al., 2010, Valdameri
et al., 2012, Redda et al., 2014) and others were evaluated
as monoamine oxidase inhibitors (Gaspar et al., 2011) or
adenosine receptor ligands (Gaspar et al., 2012).
Besides, the association between cancer and inﬂamma-
tion has long been established (Balkwill and Mantovani,
2012). For instance, the involvement of the 5-lipoxygenase
enzyme (5-LOX) and its products have been implicated in
the development and progression of colon cancer (Sou-
maoro et al., 2006). 5-LOX has been reported to induce
inﬂammation via the catalysis of the production of leuko-
trienes from arachidonic acid (Shimizu et al., 1984) and it is
therefore an important target for mechanism-based drugs for
the treatment of inﬂammatory disorders, often associated
with other diseases including cancer. Therefore, anti-
inﬂammatory agents that inhibit leukotriene production may
have a beneﬁcial effect in both the prevention and treatment
of cancer (Aggarwal et al., 2006).
In the present study, we synthesized 21 substituted
chromone carboxamides, among which 12 are newly
described, and evaluated their potency to inhibit the pro-
liferation of breast, ovarian, and colon cancer cell lines. Our
compounds were also screened for their anti-inﬂammatory
activity as putative inhibitors of 5-LOX. Additionally, an in
silico study of the “drug-likeliness” properties for our
derivatives was carried out by investigating their Lipinski
parameters (Lipinski et al., 1997) and calculating their
ligand efﬁciency values (Abad-Zapatero, 2007) to discuss
structure–activity relationships (SAR).
Materials and methods
Chemistry
Melting points were determined on a DSC-50 Shimadzu
apparatus (Kyoto, Japan). Infra-red spectra were recorded
on a Perkin–Elmer Spectrum One fourier transform infrared
spectrometer (Perkin–Elmer, USA). Proton nuclear mag-
netic resonance (1H NMR) (300MHz) and 13C NMR
(75MHz) spectra were obtained in CDCl3 or DMSO-d6 on
a DPX 300 spectrometer (Brüker Biosciences, USA), and
peak positions are given as s (singlet), d (doublet), t (triplet),
q (quadruplet) or m (multiplet). Chemical shift (δ) values
are given in parts per million. Reactions were monitored by
thin-layer chromatography (TLC) using pre-coated silica
gel plates 60 F-254. All yields are calculated for analytically
pure materials. The microanalyses were performed in the
Microanalytical Laboratory of ENSIACET in Toulouse,
France, and the results obtained were within ±0.4 % of the
theoretical values. Mass spectra, electrospray ionization-
method, were recorded on DSQ Thermo Fisher Scientiﬁc
mass spectrometer; signals were given as m/z.
Commercially available chromone-2-carboxylic acids
1a–1e, amine derivatives and all other reagents were pur-
chased from Acros Organics (Halluin, France) and used
without additional puriﬁcation. Chemical structures were
conﬁrmed by infrared (IR), 1H NMR, 13C NMR, and
ESI–MS.
The physico-chemical properties of compounds pre-
viously described 3a, 3c, 3d, 3e (Ellis and Shaw, 1972), 4a,
5a (Gaspar et al., 2011), 8a (Gaspar et al., 2011), 9a
(Gaspar et al., 2012), and 10a (Gaspar et al., 2012) are in
agreement with the literature data.
General procedure for the synthesis of acyl chloride 2
4-oxo-4H-1-benzopyran-2-carbonyl chloride derivatives
were prepared according to a previously described method
(Payard, 1973). Phosphorus pentachloride (0.028 mol; 1.1
equiv.) was added to a solution of substituted chromone-2-
carboxylic acid (0.025 mol) in dry cyclohexane (50 mL).
The mixture was stirred under reﬂux for 1 h with the for-
mation of the corresponding acyl chloride. After cooling,
the formed solid was ﬁltered and used without puriﬁcation.
General procedure for the synthesis of compounds 3–14
An equimolar amount of the suitable acyl chloride was
slowly added to a stirred solution of the corresponding amine
(0.015mol) in dry dichloromethane (DCM) (ammonium
hydroxide, aniline, propylamine, 3-ethylaniline, 4-methyla-
niline, 4-chloroaniline, 4-ﬂuoroaniline, 4-hydroxyaniline,
4-amino-α-diethylamino-O-cresol dihydrochloride, N,N-die-
thylpentyl-2,5-diamine, aminomorpholine, 1-(pyrrolidino-
carbonylmethyl)piperazine) in presence of triethylamine
(1 equiv.). The solution was stirred at room temperature and
monitored by TLC. The mixture was washed with water,
10% Na2CO3 and brine. Puriﬁcation by ﬂash silica gel
chromatography (0–8% MeOH in DCM) provided the
desired amides.
6-Fluoro-4-oxo-4H-1-benzopyran-2-carboxamide (3b)
Yield: 91 %; m.p.: 131 °C; IR (KBr) v cm−1: 3362 (NH2),
3073, 3050, 2927 (CH), 1738, 1696 (CONH2), 1635 (CO),
1624 (C=C); 1H NMR (CDCl3): δ 6.95 (s, 1H, H3), 7.80–
7.94 (m, 3H, H5, H7, H8), 8.33, and 8.70 (2s, 2H, NH2);
13C
NMR (DMSO-d6) δ: 177.30 (C4), 161.02 (C6), 158.45 (C2),
156.51 (CO–NH2), 152.04 (C8a), 125.29 (C4a), 123.47 (C7),
122.16 (C8), 110.17 (C3), 109.88 (C5); MS (m/z) 208.0 [M
+H]+. Anal. calcd. for C10H6FNO3: C, 57.98; H, 2.92; N,
6.76 %. Found: C, 57.83; H, 2.97; N, 6.84 %.
6-Fluoro-N-propyl-4-oxo-4H-chromene-2-carboxamide
(4b) Yield: 32 %; m.p.: 196 °C; IR (KBr) v cm−1: 3412
(NH), 3303, 2964, 2936, 2879 (CH, CH2, CH3), 1686
(CONH), 1642 (CO), 1618, 1540 (C=C); 1H NMR
(DMSO-d6): δ 0.91 (t, 3H, CH3, J= 7.5Hz), 1.57 (m, 2H,
CH2–CH2–CH3,), 3.26 (m, 2H, NH–CH2), 6.83 (s, 1H, H3),
7.71–7.86 (m, 3H, H5, H7, H8), 9.14 (s br, 1H, NH);
13C
NMR (DMSO-d6): δ 177.25 (C4), 160.89 (C6), 158.45 (C2),
156.46 (CO–NH), 152.00 (C8a), 125.31 (C4a), 123.72 (C7),
122.14 (C8), 110.15 (C3), 109.91 (C5), 41.47, 22.57 (2
CH2), 11.83 (CH3); MS (m/z) 250.0 [M+H]
+. Anal. calcd.
for C13H12FNO3: C, 62.65; H, 4.85; N, 5.62 %. Found: C,
62.76; H, 4.97; N, 5.46 %.
6-Bromo-N-propyl-4-oxo-4H-chromene-2-carboxamide
(4d) Yield: 33 %; m.p.: 210 °C; IR (KBr) v cm−1: 3291
(NH), 3075, 2965, 2932, 2873 (CH, CH2, CH3), 1687
(CONH), 1646 (CO), 1600, 1536 (C=C); 1H NMR
(DMSO-d6): δ 0.90 (t, 3H, CH3, J= 7.4 Hz), 1.57 (m, 2H,
CH2–CH2–CH3), 3.26 (m, 2H, NH–CH2), 6.85 (s, 1H, H3),
7.71 (d, 1H, H8, J= 8.9 Hz), 8.06 (dd,1H, H7, J= 8.8, 2.5
Hz), 8.11 (d, 1H, H5, J= 2.5 Hz), 9.14 (s br, 1H, NH);
13C
NMR (DMSO-d6): δ 176.61 (C4), 159.07 (C2), 156.40
(CO–NH), 154.51 (C8a), 138.03 (C7), 127.48 (C5), 125.57
(C4a), 121.90 (C8), 118.85 (C6), 110.85 (C3), 41.49, 22.58
(2 CH2), 11.85 (CH3); MS (m/z) 310.0 and 312 [M+H]
+.
Anal. calcd. for C13H12BrNO3: C, 50.34; H, 3.90; N, 4.52%.
Found: C, 50.45; H, 3.79; N, 4.63 %.
N-(3′-ethylphenyl)-4-oxo-4H-chromene-2-carboxamide
(6a) Yield: 71 %; m.p.: 168 °C; IR (KBr) v cm−1: 3268
(NH), 2960, 2927, 2868 (CH, CH2, CH3), 1682 (CONH),
1640 (CO), 1615, 1540 (C=C); 1H NMR (CDCl3) δ: 1.29 (t,
3H, CH3, J= 7.6 Hz), 2.71 (q, 2H, CH2, J= 7.6 Hz), 7.09
(d, 1H, H8, J= 7.5 Hz), 7.32 (s,1H, H3), 7.35 (t, 1H, H5’,
J= 7.8 Hz), 7.49–7.64 (m, 4H, H6, H2’ H4’, H6’), 7.79 (td,
1H, H7, J= 7.2, 1.7 Hz), 8.27 (dd, 1H, H5, J= 7.9, 1.6 Hz),
8.54 (s br, 1H, NH); 13C NMR (DMSO-d6): δ 177.79 (C4),
158.08 (C2), 156.19 (CO-NH), 155.62 (C8a), 144.90 (C3′),
137.99 (C1′), 135.49 (C7), 129.19 (C5′), 126.56 (C6),
125.39 (C5), 124.94 (C4′), 124.15 (C4a), 120.89 (C2′),
119.49 (C8), 118.97 (C6′), 111.48 (C3), 28.68 (CH2), 15.94
(CH3); MS (m/z) 294.1 [M+H]
+. Anal. calcd. for
C18H15NO3: C, 73.71; H, 5.15; N, 4.78 %. Found: C, 73.59;
H, 5.28; N, 4.92 %.
6-Fluoro-N-(3′-ethylphenyl)-4-oxo-4H-chromene-2-carbox-
amide (6b) Yield: 54 %; m.p.: 198 °C; IR (KBr) v cm−1:
3280 (NH), 3081, 2962, 2929, (CH, CH2, CH3), 1685
(CONH), 1637 (CO), 1612, 1593, 1543 (C=C); 1H NMR
(DMSO-d6): δ 1.21 (t, 3H, CH3, J= 7.6 Hz), 2.64 (q, 2H,
CH2, J= 7.6 Hz), 6.98 (s, 1H, H3), 7.06 (d, 1H, H4’, J= 7.6
Hz), 7.33 (t, 1H, H5′, J= 7.6 Hz), 7.64 (m, 2H, H2′, H6′),
7.77 (dd, 1H, H8, J= 8.3, 3.1 Hz), 7.85 (td, 1H, H7, J= 8.1,
3.1 Hz), 7.95 (dd, 1H, H5, J= 9.2, 4.4 Hz), 10.68 (s br, 1H,
NH); 13C NMR (DMSO-d6): δ 177.24 (C4), 160.97 (C6),
158.53 (C2), 156.39 (CO-NH), 152.03 (C8a), 144.94 (C3′),
137.89 (C1′), 129.22 (C5′), 125.38 (C4′), 125.31 (C4a),
123.55 (C7), 122.30 (C8), 120.88 (C2′), 118.96 (C6′), 110.68
(C3), 109.93 (C5) 28.67 (CH2), 15.94 (CH3); MS (m/z) 312.1
[M+H]+. Anal. calcd. for C18H14FNO3: C, 69.45; H, 4.53;
N, 4.50 %. Found: C, 69.57; H, 4.65; N, 4.39 %.
6-Bromo-N-(3′-ethylphenyl)-4-oxo-4H-chromene-2-car-
boxamide (6d) Yield: 52 %; m.p.: 227 °C; IR (KBr)
v cm−1: 3267 (NH), 3075, 2961, 2960, 2927, (CH, CH2,
CH3), 1683 (CONH), 1637 (CO), 1608, 1597, 1541 (C=C);
1H NMR (DMSO-d6): δ 1.34 (t, 3H, CH3, J= 7.6 Hz), 2.76
(q, 2H, CH2, J= 7.6 Hz), 7.13 (s, 1H, H3), 7.19 (d, 1H, H4′,
J= 7.6 Hz), 7.46 (t, 1H, H5′, J= 7.7 Hz), 7.75 (m, 2H, H2′,
H6′), 7.96 (d, 1H, H8, J= 8.9 Hz), 8.22 (dd, 1H, H7, J= 8.9,
2.5 Hz), 8.28 (d, 1H, H5, J= 2.5 Hz), 10.4 (s br, 1H, NH);
13C NMR (DMSO-d6): δ 176.68 (C4), 157.80 (C2), 156.38
(CO–NH), 154.58 (C8a), 144.95 (C3′), 138.16 (C7), 137.88
(C1′), 129.23 (C5′), 127.49 (C5), 125.63 (C4a), 125.04 (C4′),
122.17 (C8), 120.88 (C2′), 119.04 (C6), 118.97 (C6′),
111.51 (C3), 28.67 (CH2), 15.94 (CH3); MS (m/z) 372.0 and
374.0 [M+H]+. Anal. calcd. for C18H14BrNO3: C, 58.08; H,
3.79; N, 3.76 %. Found: C, 58.29; H, 3.64; N, 3.89 %.
N-(3′-ethylphenyl)-6-methyl-4-oxo-4H-chromene-2-car-
boxamide (6e) Yield: 33 %; m.p.: 202 °C; IR (KBr) v
cm−1: 3326 (NH), 3074, 2928, 2850, (CH, CH2, CH3), 1681
(CONH), 1637 (CO), 1610, 1594, 1541 (C=C); 1H NMR
(DMSO-d6): δ 1.21 (t, 3H, CH2-CH3, J= 7.6 Hz), 2.48 (s,
3H, CH3), 2.64 (q, 2H, CH2, J= 7.6 Hz), 6.94 (s, 1H, H3),
7.07 (d, 1H, H4′, J= 8.0 Hz), 7.33 (t, 1H, H5′, J= 8.0 Hz),
7.65 (m, 2H, H2′, H6′), 7.75 (m, 2H, H7, H8), 7.87 (s, 1H,
H5), 10.66 (s br, 1H, NH);
13C NMR (DMSO-d6): δ 177.72
(C4), 158.13 (C2), 156.04 (CO–NH), 153.88 (C8a), 144.89
(C3′), 137.99 (C7), 136.56 (C1′), 136.29 (C6), 129.18 (C5′),
124.92 (C4′), 124.62 (C5), 123.86 (C4a), 120.86 (C2′),
119.27 (C8), 118.94 (C6′), 111.31 (C3), 28.68 (CH2), 20.94
and 15.94 (2 CH3); MS (m/z) 308.1 [M+H]
+. Anal. calcd.
for C19H17NO3: C, 74.25; H, 5.58; N, 4.56 %. Found: C,
74.37; H, 5.42; N, 4.69 %.
N-(4′-ﬂuorophenyl)-4-oxo-4H-chromene-2-carboxamide
(7a) Yield: 48 %; m.p.: 222 °C; IR (KBr) v cm−1: 3338
(NH), 3138, 3072 (CH), 1697 (CONH), 1630 (CO), 1573,
1508 (C=C); 1H NMR (DMSO-d6): δ 6.98 (s,1H, H3), 7.27
(m, 2H, H3′, H5′), 7.57 (m, 1H, H6), 7.82–7.85 (m, 4H, H7,
H8, H2′, H6′), 8.08 (dd, 1H, H5, J= 7.9, 1.6 Hz), 10.82
(s,1H, NH); 13C NMR (DMSO-d6): δ 177.73 (C4), 160.66
(C4′), 158.25 (C2), 156.01 (CO–NH), 155.60 (C8a), 135.48
(C7), 134.35 (C1′), 126.55 (C6), 125.39 (C5), 124.14 (C4a),
123.60 (C6′), 123.52 (C2′), 119.47 (C8), 116.03 (C5′),
115.80 (C3′), 111.56 (C3); MS (m/z) 284.0 [M+H]
+. Anal.
calcd. for C16H10FNO3: C, 67.84; H, 3.56; N, 4.94 %.
Found: C, 67.53; H, 3.62; N, 4.88 %.
N-[3-((diethylamino)methyl)-4-hydroxyphenyl]-4-oxo-4H-
chromene-2-carboxamide (11a) Yield: 26 %; m.p.: 186 °
C; IR (KBr) v cm−1: 3470 (OH), 3339 (NH), 3075, 2975,
2827 (CH, CH2, CH3), 1685 (CONH), 1638 (CO), 1616,
1560, 1512 (C=C); 1H NMR (DMSO-d6): δ 1.05 (t, 6H,
CH2–CH3, J= 6.8 Hz), 2.56 (m, 4H, N–CH2–CH3), 3.33 (s
br, 1H, OH), 3.73 (s, 2H, Ar–CH2–N), 6.73 (d, 1H, H5′, J=
8.4 Hz), 6.94 (s, 1H, H3), 7.54 (m, 2H, H6 and H6′), 7.70 (s,
1H, H2′), 7.85 (d, 1H, H8, J= 8.7 Hz), 7.93 (t, 1H, H7, J=
7.5 Hz), 8.08 (d, 1H, H5, J= 6.9 Hz), 10.56 (s br, 1H, NH);
13C NMR (DMSO-d6): δ 177.92 (C4), 157.70 (C2), 156.36
(CO–NH), 155.61 (C8a), 154.92 (C4′), 135.54 (C7), 129.32
(C1′), 129.30 (C6′), 126.52 (C6), 125.39 (C5), 125.37 (C3′),
124.07 (C4a), 123.29 (C2′), 119.48 (C8), 115.91 (C5′),
111.27 (C3), 53.19 (Ar–CH2–N), 46.65 (N–CH2), 10.51
(CH3); MS (m/z) 367.2 [M+H]
+. Anal. calcd. for
C21H22N2O4: C, 68.84; H, 6.05; N, 7.65 %. Found: C,
68.92; H, 6.24; N, 7.52 %.
N-(5-(diethylamino)pent-2-yl)-4-oxo-4H-chromene-2-car-
boxamide (12a) Yield: 57 %; m.p.: 110 °C; IR (KBr) v
cm−1: 3475, 3428, 3370 (NH), 2978, 2939, 2633 (CH, CH2,
CH3), 1679 (CONH), 1647 (CO), 1608, 1572, 1528 (C=C);
1H NMR (DMSO-d6): δ 1.19 (t, 6H, CH2–CH3, J= 7.2 Hz),
1.23 (d, 3H, CH–CH3, J= 6.6 Hz), 1.62 (m, 4H, CH–CH2–
CH2–CH2–N), 3.05 (m, 6H, 3 CH2–N), 4.05 (m, 1H, CH),
6.85 (s, 1H, H3), 7.55 (td, 1H, H6, J= 7.9, 0.9 Hz), 7.82 (d,
1H, H8, J= 7.8 Hz), 7.91 (td, 1H, H7, J= 8.5, 1.6 Hz), 8.05
(dd, 1H, H5, J= 7.9, 1.3 Hz), 10.13 (s br, 1H, NH);
13C
NMR (DMSO-d6): δ 177.86 (C4), 159.02 (C2), 156.27 (CO-
NH), 155.60 (C8a), 135.38 (C7), 126.49 (C6), 125.30 (C5),
124.05 (C4a), 119.51 (C8), 110.97 (C3), 50.76 and 46.50 (2
CH2), 45.42 (CH), 32.96 (CH2), 20.89 (CH3) 20.48 (CH2),
8.82 (CH3); MS (m/z) 331.2 [M+H]
+. Anal. calcd. for
C19H26N2O3: C, 69.06; H, 7.93; N, 8.48 %. Found: C,
69.23; H, 7.72; N, 8.33 %.
N-morpholino-4-oxo-4H-chromene-2-carboxamide (13a)
Yield: 57 %; m.p.: 271 °C; IR (KBr) v cm−1: 3219 (NH),
3061, 2962, 2938, 2874 (CH), 1684 (CONH2), 1644 (CO),
1620, 1607, 1511 (C=C); 1H NMR (DMSO-d6): δ 2.94 (t,
4H, O–CH2–CH2–N, J= 4.6 Hz), 3.69 (t, 4H, O–CH2–
CH2–N, J= 4.6 Hz), 6.82 (s, 1H, H3), 7.55 (td, 1H, H6, J=
8.0, 1.0 Hz), 7.76 (d, 1H, H8, J= 7.9 Hz), 7.90 (m, 1H, H7),
8.05 (dd, 1H, H5, J= 7.9, 1.6 Hz), 10.20 (s br, 1H, NH);
13C
NMR (DMSO-d6): δ 177.69 (C4), 157.30 (C2), 156.15
(CO–NH), 155.57 (C8a), 135.51 (C7), 126.57 (C6), 125.39
(C5), 124.09 (C4a), 119.34 (C8), 111.25 (C3), 66.39 (2 CH2),
54.63 (2 CH2); MS (m/z) 275.0 [M+H]
+. Anal. calcd. for
C14H14N2O4: C, 61.31; H, 5.14; N, 10.21 %. Found: C,
61.45; H, 5.06; N, 10.36 %.
2-[4(N-pyrrolidinylcarbonylmethyl)-piperazinylcarbonyl]-
4H-chromen-4-one (14a) Yield: 55 %; m.p.: 117 °C; IR
(KBr) v cm−1: 3052, 2973, 2955, 2867, 2820 (CH, CH2,
CH3), 1662 (CONH), 1644 (CO), 1617, 1573, 1510 (C=C);
1H NMR (CDCl3): δ 1.89 and 1.98 (2m, 4H, H3″, H4″), 2.7
(m, 4H, H2″, H5″), 3.22 (s, 2H, N–CH2–CO–), 3.48 (m, 4H,
H3′, H5′), 3.62, and 3.85 (2m, 4H, H2′, H6′), 6.53 (s, 1H,
H3), 7.46 (t, 1H, H6, J= 7.1 Hz), 7.52 (d, 1H, H8, J= 8.6
Hz), 7.76 (td, 1H, H7, J= 7.1, 1.7 Hz), 8.25 (dd, 1H, H5,
J= 8.0, 1.5 Hz); 13C NMR (DMSO-d6): δ 177.08 (C4),
167.66 (CO–CH2), 160.52 (CO–NH), 158.46 (C2), 155.91
(C8a), 135.51 (C7), 126.57 (C6), 125.39 (C5), 124.16 (C4a),
119.08 (C8), 111.01 (C3), 60.22 (CO–CH2–N), 53.06 and
52.23 (2C pyrrolidine), 46.99, 45.99, 45.81 and 42.20 (4C
piperazine), 26.16 and 24.12 (2C pyrrolidine); MS (m/z)
370.2 [M+H]+. Anal. calcd. for C20H23N3O4: C, 65.03; H,
6.28; N, 11.37 %. Found: C, 65.21; H, 6.15; N, 11.25 %.
Pharmacology
Anti-inﬂammatory activity
The anti-inﬂammatory activity of compounds was deter-
mined by the inhibition of soybean lipoxygenase. Chro-
mone derivatives were dissolved in dimethyl sulfoxide
(DMSO) and solutions were diluted in sodium phosphate
buffer (pH 7.4). Diluted solutions of compounds (20 μL)
were mixed individually with 30 μL of sodium phosphate
buffer containing 5-LOX and 60 μL of linoleic acid (3.5
mM) in a 96-well microliter plate. Addition of 90 μL buffer
gave a total volume of 200 μL and a ﬁnal concentration of
chromone carboxamide of 100 μM. The DMSO concentra-
tion did not exceed 1 %. The mixture was incubated at 25 °
C for 10 min, and the absorbance was recorded at 234 nm
using a Thermo Scientiﬁc Multiskan GO Microplate Spec-
trophotometer. The absorption changes with the conversion
of linoleic acid to 13-hydroperoxyoctadeca-9,11-dienoate.
Nordihydroguaiaretic acid (NDGA) was used as positive
control. Percentage inhibition of enzyme was determined by
comparison of rates of reaction of samples relative to blank
sample using the formula (E−S)/E × 100, where E is the
activity of enzyme without test sample and S is the activity
of enzyme with test sample. The percentage of inhibition of
each compound was determined in triplicate.
Cytotoxicity evaluation
The cytotoxicity of compounds was estimated on human
cancer cell lines (MCF-7, HCT-116, OVCAR, IGROV)
using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) assay. Cells were distributed in 96-well
plates at 3 × 104 cells/well in 100 μL culture medium, and
then 100 μL of medium containing the chromone
carboxamide at various concentrations were added. MTT is
a yellow water-soluble tetrazolium salt, which metabolically
active cells convert to water-insoluble dark blue formazan by
reductive cleavage of the tetrazolium ring. All compounds
were dissolved in DMSO followed by dilution in buffer so
that the DMSO concentration did not exceed 1%. The level
of blue formazan is then used as indirect index of cell
density. The optical density of each sample was measured
with a Thermo Scientiﬁc Multiskan GO Microplate Spec-
trophotometer at 500 nm. Four replicates were performed for
each sample. Tamoxifen was used as positive control.
Results and discussion
Chemistry
Chromone carboxamides derivatives were obtained by
functionalization of the chromone nucleus at position C2 of
the γ-pyrone ring.
Structural modiﬁcations have been made in order to
evaluate the SAR on cytotoxicity and 5-LOX inhibition.
Particularly, (i) the introduction of a halide or methyl group
on the 6-position of the chromone nucleus (R1, scheme 1),
(ii) the side chain nature, either aliphatic or aromatic (R2),
(iii) the substitution on the aromatic moiety, and (iv) the
functionalization of the hydroxyl group have been con-
sidered. The molecular diversity in this library of com-
pounds was further increased by preparing analogs 12a,
13a, and 14a bearing nitrogen-containing side chains.
Syntheses were carried out starting from 6-substituted 2-
chromone carboxylic acids, prepared according to a pre-
viously described method (Payard et al., 1974). The car-
boxamide derivatives were prepared in a two-step process,
involving ﬁrst the conversion, in quantitative yield, of the
carboxylic acid into the acylchloride 2 using PCl5 (Payard,
1973), and then the condensation with the appropriate
amine to give amides 3–14 (scheme 1). The main advantage
of this synthetic procedure is that no coupling reagents are
needed. Chromone carboxamides were synthesized in a
range of 30–90 % yields, similar to those reported with the
use of coupling agents such as phosphonium salts (BOP or
PyBOP) (Gaspar et al., 2011). Their chemical structures
were conﬁrmed by IR, 1H NMR, 13C NMR and ESI–MS.
Reactions conditions: i) PCl5/dry cyclohexane; ii) R2-
NH2/TEA/dry DCM.
Pharmacology
Cytotoxicity
Twenty one chromone carboxamide derivatives were
assayed for their in vitro anti-proliferative effect against
four human cancer cell lines: MCF-7 (hormone dependent
breast cancer), OVCAR and IGROV (ovary cancer) and
HCT-116 (colon cancer) using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay as
described by Mosmann (1983) with modiﬁcations (Bekir
et al., 2013). The results, expressed as IC50 values (μM),
i.e., the concentration required to inhibit cell proliferation
by 50 % after exposure of cells to test compounds, are
summarized in Table 1 and tamoxifen was used as
reference.
Among these compounds, 13 showed good cytotoxic
activity against at least one cancer cell line (IC50≤ 10 μM).
In the case of the breast cancer cell line MCF-7, ﬁve
compounds were active with the best antiproliferative
activity observed for 4b (IC50= 0.9 μM). Eight compounds
were active against OVCAR cells (lowest IC50 for 4b and
11a= 5.1 μM), eight derivatives were cytotoxic against
IGROV cells (lowest IC50 for 4b and 10a= 3.2 μM), and
four compounds were active against colon HTC-116 cells
(lowest IC50 for 4d= 4.5 μM).
The tests showed that the primary amide analogs 3a–3e
are not cytotoxic, except the 6-ﬂuorinated compound 3b,
which had an interesting activity against the two cancer cell
lines OVCAR and IGROV (IC50= 10.1 and 11.8 μM,
respectively).
Amide alkylation by a propyl side chain (compounds
4a–4d) had a signiﬁcantly positive impact on the cytotoxic
activity. For instance the 6-ﬂuorinated propyl carboxamide
4b (IC50 range: 0.9–22.2 μM) was more cytotoxic than its
primary analog 3b (IC50 range: 10.1–44.2 μM). Compound
4b was also the most potent compound against hormone
dependent breast cancer cells MCF-7 with an IC50 value in
the same range as tamoxifen (IC50= 0.9 and 0.39 μM,
respectively). Regarding the non-substituted chromone
series (R1=H), alkylation by a 3-ethylphenyl ring also had
a positive impact as compound 6a exhibited IC50 values
against the four cell lines in the same range as the propyl
carboxamide derivative 4a (IC50 range: 5.3–18.0 μM).
However, the positive effect of the 6-ﬂuoro substituent on
activity showed with compounds 3b and 4b was not
observed with derivative 6b, less active than its 6-bromi-
nated and 6-methylated analogs (6d and 6e).
The beneﬁcial effect of ﬂuorine seen with the 6-ﬂuoro
chromone series was not observed when the ﬂuorine atom was
placed on the phenylcarboxamide side chain (compound 7a)
as the toxicity towards the tested cell lines was not enhances
compared to the chloro (8a) and methyl (9a) analogs.
The presence of a hydroxyl group in the para position of
the phenylcarboxamide produced a beneﬁcial effect as
compound 10a showed IC50 values from 3.2 to 12.3 μM.
On adding a methyldiethylamino chain in the meta position
(compound 11a), only the activity against OVCAR cells
was conserved (IC50= 5.1 μM).
To widen the panel of structures, we also studied chro-
mone carboxamides bearing various non-aromatic nitrogen-
containing side chains: N,N-(diethyl)pentanamine, mor-
pholine and N-substituted piperazine (12a–14a). The impact
of these groups on the activity was not the same depending
on the cell line but one can note that the IC50 values were
kept below 10 μM against at least one cell line.
Overall, while several compounds in the present library
possess IC50 values below 10 μM, none of them displays
good selectivity, i.e., activity against one cell line 10-fold
higher than the three other cell lines.
Anti-inﬂammatory activity
In order to study the ability of compounds 3–14 to directly
inhibit the catalytic activity of 5-LOX, a cell-free assay
using puriﬁed 5-LOX enzyme in the presence of 100 μM of
the chromone derivative was applied, according to the
method described by Baylac and Racine (Baylac and
Racine, 2003) with modiﬁcations. Among 20 chromone
carboxamide derivatives tested as putative inhibitors of the
5-LOX enzyme, 10 were totally inactive or showed low
activity (<20 %) and 10 showed moderate to good activity
(Table 1).
The 6-ﬂuorinated compound 3b showed interesting
inhibition (79.9 %). Here again, the effect of a 6-ﬂuoro
substituent was positive for 5-LOX inhibition compared to
its 6-Cl, 6-Br, and 6-methyl analogs (3c–3e). The presence
of the propyl side chain (4b) led to a decreased activity
(68.0 % instead of 79.9 % for 3b).
Alkylation with a phenyl moiety, either substituted or not
with ethyl, ﬂuoro, chloro, or methyl groups (compounds
6a–e, 7a–9a) had a major negative impact on the anti-
inﬂammatory activity. However, using a para phenol as
alkylating group (compound 10a) had a positive effect on
the anti-inﬂammatory activity as 5-LOX inhibition
increased up to 73.5 % compared to 55.2 % for the primary
amide homolog 3a. The beneﬁcial effect of a para phenol
Reactions conditions: i) PCl5/dry cyclohexane; ii) R2-NH2/TEA/dry DC
R1 R2
3a H -NH2
3b F -NH2
3c Cl -NH2
3d Br -NH2
3e CH3 -NH2
4a H -NH-C3H7
4b F -NH-C3H7
4d Br -NH-C3H7
5a H -NH-Ph
6a H -NH-(3’-C2H5)-Ph
6b F -NH-(3’-C2H5)-Ph
6d Br -NH-(3’-C2H5)-Ph
6e CH3 -NH-(3’-C2H5)-Ph
7a H -NH-(4’-F)-Ph
8a H -NH-(4’-Cl)-Ph
9a H -NH-(4’-CH3)-Ph
10a H -NH-(4’- OH)-Ph
11a H -NH-(4’-OH, 3’-CH2-N(C2H5)2)-Ph
12a H -NH-CH(CH3)-(CH2)3-N(C2H5)2
13a H -NH-morpholino
14a H -N-2-(4-pyrrolidinylcarbonylmethyl)-piperazinyl
Scheme 1 Synthesis of
compounds 3–14
Table 1 In vitro cytotoxicity against four human cancer cell lines and anti-inﬂammatory activity of compounds 1, 3–14
Antiproliferative activity IC50 (μM) Anti-inﬂammatory
activity %
inhibition
(100 μM)
R1 R2 MCF-7 OVCAR IGROV HCT-116 5-Lipoxygenase
1a H OH >100 >100 20.2± 4.1 14.4± 1.3 ND
3a H NH2 >100 >100 >100 >100 55.2± 4.0
3b F NH2 44.2± 5.0 10.1± 1.3 11.8± 1.3 33.2± 2.2 79.9± 6.6
3c Cl NH2 89.2± 13.2 >100 >100 >100 41.8± 6.1
3d Br NH2 >100 >100 >100 >100 15.5± 1.2
3e CH3 NH2 80.2± 13.2 >100 >100 >100 12.9± 0.6
4a H 11.2± 1.1 10.1± 1.1 5.4± 0.3 20.2± 1.1 67.2± 3.4
4b F 0.9± 0.0 5.1± 0.3 3.2± 0.1 22.2± 2.2 68.0± 1.8
4d Br 12.6± 1.0 25.2± 2.3 7.2± 0.4 4.5± 0.2 30.5± 5.1
5a H >100 >100 >100 >100 ND
6a H 5.3± 0.6 8.0± 0.4 18.0± 2.0 14.2± 0.9 NA
6b F 56.1± 6.4 5.8± 0.3 13.2± 1.2 32.3± 4.4 NA
6d Br 6.3± 0.4 20.1± 3.3 8.0± 1.2 >100 NA
6e CH3 18.0± 2.2 9.2± 1.3 5.9± 0.0 >100 NA
7a H 63.2± 5.3 >100 18.0± 2.1 25.2± 3.2 NA
8a H >100 >100 22.1± 1.2 9.0± 0.4 NA
9a H >100 >100 25.4± 2.2 11.3± 1.2 NA
10a H 12.3± 1.0 6.3± 0.2 3.2± 0.0 9.0± 1.3 73.5± 3.4
was reduced when a N-diethylmethyl side chain was added
in the meta position of the phenyl group (52.0 % for com-
pound 11a).
Amidation using other nitrogen containing side chains
(N-diethylpentyl 12a, morpholinyl 13a, and substituted
piperazinyl 14a) showed good activity with 5-LOX inhi-
bition from 48.6 % up to 68.8 %.
Theoretical evaluation of “drug-likeliness” properties
To predict their overall “drug-likeness”, an in silico com-
putational study of the synthesized chromone carboxamides
3–14 was performed by determining Lipinski parameters
(Lipinski et al., 1997) using the molinspiration online
software (www.molinspiration.com) (Table 1 of supple-
mentary material). To better understand the therapeutic
potential of chromone derivatives, we also calculated their
ligand efﬁciency (LE) for all the cell lines (Table 2 of
supplementary material). LE is a measure of the in vitro
biological activity corrected for the physico-chemical
properties of the molecule and quantify how effectively the
molecule uses its structural features in binding the target.
LE is therefore a useful metric to normalize the afﬁnities of
hits to identify the best starting points for optimization, i.e.,
those with the highest LE values (Hopkins et al., 2014).
From the data obtained, one can observe that all the
chromone derivatives possess LogP values compatible with
those required to cross membranes and no violations of
Lipinski’s rules were found (Table 2), thus making our
chromone derivatives promising therapeutic agents with a
good potential for eventual development as orally active
drug candidates. Lipophilicity does seem to play a sig-
niﬁcant role for 5-LOX inhibition as, except for 11a, deri-
vatives with logP ≥ 3.01 were totally inactive (compounds
6a–9a) and the six most potent chromone carboxamides had
a logP value < 2.47.
Overall, the lowest IC50 value was displayed by com-
pound 4b against MCF-7 cell line. In order to see if this
compound is the one which should be selected as a lead for
further investigations, we calculated the LE values for all
compounds against this cell line. Results showed that LE
values are in the range 0.36–0.46 kcal/mol/non-H atom.
Table 1 continued
Antiproliferative activity IC50 (μM) Anti-inﬂammatory
activity %
inhibition
(100 μM)
R1 R2 MCF-7 OVCAR IGROV HCT-116 5-Lipoxygenase
11a H 34.8± 3.2 5.1± 0.3 12.0± 0.4 40.0± 3.0 52.0± 4.9
12a H 40.2± 2.0 10.4± 1.2 6.8± 0.4 36.2± 3.1 48.6± 2.3
13a H 8.3± 0.1 25.3± 2.4 13.1± 1.2 5.8± 1.1 68.8± 4.6
14a H 6.0± 0.5 28.0± 2.2 10.1± 0.2 31.3± 3.3 62.3± 2.9
Tamoxifen 0.39± 0.01 0.52± 0.04 0.82± 0.10 0.37± 0.02 —
NDGA (13 μM) — — — — 50.0± 2.7
NDGA nordihydroguaiaretic acid, NA not active, ND not determined
The highest LE value (0.46 kcal/mol/non-H atom) was
observed for compound 4b. In addition, this compound also
exhibits good LE values for the three other cell lines (0.36–
0.42 kcal/mol/non-H atom). As compound 4b is relatively
small, this result means that this molecule can be further
improved for enhanced potency.
Conclusion
In this study, 21 chromone carboxamide derivatives were
synthesized using simple and affordable chemistry and
evaluated for anti-proliferative activity against four human
cancer cells. Among these compounds, 13 showed IC50
values below 10 μM against at least one cancer cell line.
Compound 4b was the most promising one with cytotoxic
effect against breast cancer cell line MCF-7 equivalent to
tamoxifen’s. Among the four cancer cell lines, the ovarian
IGROV line was the most sensitive to the tested com-
pounds. Chromone carboxamide derivatives with a 6-ﬂuoro
substituent on the chromone nucleus (R1) or propyl or 3-
ethylphenyl groups on the amide side chain (R2) showed
better cytotoxic effect. In terms of anti-inﬂammatory
activity, hydrophilic chromone carboxamide derivatives
showed greater 5-LOX inhibition.
Overall, the physico-chemical properties (lipophilicity,
molecular weight, number of H acceptors/donnors) of
chromone carboxamides are in accordance with the general
requirements of drug discovery and development process
and LE values allow further structure optimization, with
compound 4b as a lead. Other compounds such as 6a or 10a
are also promising compounds. Therefore, this study pro-
vides a solid base for further research on chromone car-
boxamides to get more potent and selective cytotoxic
agents.
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